A New Hope in the Treatment of Plaque Psoriasis <\/p>\n
A recent study published in the New England Journal of Medicine has shed light on a potentially effective treatment for moderate-to-severe plaque psoriasis. The study investigated the efficacy of JNJ-77242113, a novel interleukin-23-receptor antagonist peptide developed by Janssen Research and Development. The results offer promising implications for patients suffering from this chronic skin condition. <\/p>\n
The study involved a total of 255 patients with moderate-to-severe plaque psoriasis. These patients were randomly assigned to receive various doses of JNJ-77242113 or a placebo over a course of 16 weeks. The primary endpoint of the study was to observe a reduction of at least 75% in the Psoriasis Area and Severity Index (PASI) score at week 16. This score is a widely accepted measure for the severity of psoriasis. <\/p>\n
The study demonstrated that JNJ-77242113 showed greater efficacy than the placebo, with a significant dose-response relationship observed. This means that as the dosage of JNJ-77242113 increased, the reduction in PASI score also increased significantly. Specifically, in the highest dose group tested of 100 mg twice daily, 79% of patients achieved a PASI 75 response. This is indeed a promising result for a phase 2 trial. <\/p>\n
As with any clinical trial, understanding the safety profile and potential adverse events of the tested drug is critical. The most common adverse events reported during this study were COVID-19 and nasopharyngitis, also known as the common cold. However, its important to note that the percentage of patients with at least one adverse event was similar in both the combined JNJ-77242113 dose group and the placebo group, suggesting that the drug may have a comparable safety profile to the placebo. <\/p>\n
JNJ-77242113 is an orally administered peptide that selectively blocks interleukin-23 signaling and downstream cytokine production. The role of interleukin-23 in the body is to regulate inflammatory responses and immune system function. By blocking its signaling, JNJ-77242113 can potentially control the overactive immune responses seen in psoriasis, thereby reducing inflammation and the severity of the condition. <\/p>\n
Following the positive results from the phase 2 trial, Johnson & Johnson has initiated the pivotal Phase 3 ICONIC clinical development program of JNJ-77242113 in adult and adolescent patients with moderate to severe plaque psoriasis. This next phase will further evaluate the drugs efficacy and safety profile in a larger patient population. <\/p>\n
The phase 2 trial results for JNJ-77242113 are indeed encouraging. With its potential efficacy and favorable safety profile, JNJ-77242113 could soon offer a new, effective oral treatment option for patients suffering from moderate-to-severe plaque psoriasis. As we await further results from the Phase 3 trial, the current findings certainly provide a beacon of hope for those affected by this chronic skin condition. <\/p>\n
<\/p>\n
See the original post here: A New Hope in the Treatment of Plaque Psoriasis A recent study published in the New England Journal of Medicine has shed light on a potentially effective treatment for moderate-to-severe plaque psoriasis. Continue reading
\nNew Hope in Treatment of Plaque Psoriasis: Study Shows Promising Results - Medriva<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"